Related Experiment Videos
Chemosensitization of mouse tumors by misonidazole
Abstract:
The chemosensitizing action of misonidazole when used in combination with chemotherapeutic drugs has been assessed in two mouse tumors. Regrowth delay has been used as the assay, and by producing dose-response curves the effect has been classified as additive or interactive. A very small additive effect was seen with bleomycin and adriamycin. A larger additive effect was seen with cyclophosphamide, and a dose dependent interaction was seen with melphalan. The misonidazole dose needed to produce these effects has a threshold of 0.5--0.75 mg/g. Two other nitroimidazoles (Ro 05-9963 and Ro 03-8799) were no more effective than MISO when used with melphalan or cyclophosphamide, even though Ro 05-9963 was much more cytotoxic as a single agent. A distinct enhancement of normal tissue toxicity (LD50/30) was observed for MISO combined with melphalan or cyclophosphamide in two strains of mice. However, the tumor sensitization was bigger than the normal tissue effect, resulting in a therapeutic gain in 3 out of 4 comparisons.
Insights
Misonidazole enhances chemotherapy by increasing tumor cell sensitivity. This combination therapy showed therapeutic gains in mouse models, suggesting improved cancer treatment potential.
Area of Science:
- Oncology
- Pharmacology
- Cancer Research
Background:
- Misonidazole (MISO) is a hypoxic cell radiosensitizer.
- Its potential to enhance chemotherapy in combination treatments requires further investigation.
Purpose of the Study:
- To evaluate the chemosensitizing effects of misonidazole when combined with various chemotherapeutic agents in mouse tumor models.
- To assess the therapeutic gain by comparing tumor sensitization with normal tissue toxicity.
Main Methods:
- Two mouse tumor models were used to assess regrowth delay as an endpoint.
- Dose-response curves were generated to classify the interaction between misonidazole and chemotherapeutic drugs (bleomycin, adriamycin, cyclophosphamide, melphalan).
- Normal tissue toxicity (LD50/30) was evaluated in two mouse strains.
Main Results:
- Misonidazole demonstrated additive effects with bleomycin and adriamycin, a larger additive effect with cyclophosphamide, and a dose-dependent interaction with melphalan.
- A threshold dose of 0.5–0.75 mg/g misonidazole was required for these effects.
- Other nitroimidazoles (Ro 05-9963, Ro 03-8799) showed no superior efficacy compared to misonidazole.
- Enhanced normal tissue toxicity was observed, but tumor sensitization was greater, leading to a therapeutic gain in 3 out of 4 comparisons.
Conclusions:
- Misonidazole exhibits chemosensitizing properties, particularly with melphalan and cyclophosphamide.
- The combination therapy offers a therapeutic gain, indicating potential for improved cancer treatment strategies.
- Further research into nitroimidazole derivatives may yield more effective chemotherapeutic enhancers.